Abstract
A new nucleosidyl-peptide antibiotic, sansanmycin, was isolated from an unidentified Streptomyces sp SS. The structure of sansanmycin was elucidated by analyses of its alkaline hydrolysate and spectroscopic analyses. Sansanmycin exhibits antibacterial activity against Mycobacterium tuberculosis H37Ra and Pseudomonas aeruginosa with MIC values of 10 and 12.5 μg/ml, respectively.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Xie, Y., Chen, R., Si, S. et al. A New Nucleosidyl-peptide Antibiotic, Sansanmycin. J Antibiot 60, 158–161 (2007). https://doi.org/10.1038/ja.2007.16
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ja.2007.16
Keywords
This article is cited by
-
A Novel Finding: 2,4-Di-tert-butylphenol from Streptomyces bacillaris ANS2 Effective Against Mycobacterium tuberculosis and Cancer Cell Lines
Applied Biochemistry and Biotechnology (2023)
-
Molecular mechanism of mureidomycin biosynthesis activated by introduction of an exogenous regulatory gene ssaA into Streptomyces roseosporus
Science China Life Sciences (2021)
-
Mechanism of action of nucleoside antibacterial natural product antibiotics
The Journal of Antibiotics (2019)
-
Rescrutiny of the sansanmycin biosynthetic gene cluster leads to the discovery of a novel sansanmycin analogue with more potency against Mycobacterium tuberculosis
The Journal of Antibiotics (2019)
-
Liposidomycin, the first reported nucleoside antibiotic inhibitor of peptidoglycan biosynthesis translocase I: The discovery of liposidomycin and related compounds with a perspective on their application to new antibiotics
The Journal of Antibiotics (2019)